skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

​Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

  • A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
  • The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
  • Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
  • Country-specific treatment algorithms and reimbursement scenarios
  • Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
  •  Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

video-thumb-sample

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
video-thumb-sample

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

  • Manage portfolio risks
  • Analyze success factors
  • Create meaningful benchmarks
video-thumb-sample

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

  • Cutting edge thought leadership
  • Expert analysis
  • Hear from news makers

Pharma Intelligence latest insights

  • In Vivo

    World In Motion The Shape Of The New Health Care Technology Ecosystem In 2022

    By Ashley Yeo 14 Jun 2018

    The health products industry, methods of care delivery and even the public's expectations for improved tools to prevent, monitor and treat disease have transformed dramatically in the past five years. The changes anticipated over a similar period ahead are potentially even more marked, with business continuity impacts for medtech and pharma concerns, according to Deloitte LLP experts who were on the circuit at health care industry events in Germany and the UK this spring.

    Topic Business strategies Digital Health

  • In Vivo

    How The EHR And New Data Streams Are Influencing Clinical Practice

    By Mark Ratner 14 Jun 2018

    A plethora of clinical studies are showing that new types of data, often captured in the EHR, can help improve the correlation between treatments and outcomes and favorably affect patient care as well as enhance drug development.

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 1

    By Jack Allen 08 Jun 2018

    Zach McLellan and Jack Allen are joined by guest analysts Dominique Fontanilla and Hardik Patel. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Datamonitor Healthcare Analyst Podcast: Post-ASCO Podcast 2

    By Jack Allen 08 Jun 2018

    Zach McLellan and Jack Allen are joined by guest analyst Maria Berezina. The group discusses key recent events that occurred at the American Society of Clinical Oncology 2018 Annual Meeting.

    Topic Cancer

  • Datamonitor Healthcare

    Approval of Sun Pharmas Yonsa in Prostate Cancer Podcast

    By Zachary McLellan 29 May 2018

    Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of Sun Pharma's Yonsa in prostate cancer, and broad market commentary on Tesaro, Gilead, Clovis, Portola, BMS and Celgene

    Topic Company analysis

  • Citeline, Scrip, Biomedtracker, Datamonitor Healthcare

    ASCO Essentials Webinar 2018 Recording

    By Mary Jo Laffler 29 May 2018

    Just in time for your 2018 ASCO Annual Meeting planning, join analysts from Datamonitor Healthcare, Biomedtracker, Citeline, Scrip, and Pink Sheet for their expert opinions on what you need to know to get the most from the meeting. Let our experts present their top picks from the thousands of abstracts being presented at ASCO.

    Topic Clinical trials

  • Datamonitor Healthcare

    Profitability Assessment of Branded Generic Inhalers

    By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

    This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

    Topic Deal trends

  • Datamonitor Healthcare

    Gene therapy

    15 May 2018

    Topic Cell and gene therapy

  • Datamonitor Healthcare

    Dyslipidemia Market Overview Webinar How the Rise of Add-on Therapies will Spur Growth of the Dyslipidemia Market

    By Jack Allen 15 May 2018

    Jack Allen, Senior Analyst, Cardiovascular and Metabolic, Datamonitor Healtcare, leads the webinar. Topics covered: Overview of the Dyslipidemia Market Treatment Options Pipeline Therapies in Development Prescribing Trends Dyslipidemia Forecast.

    Topic Dyslipidaemia

  • In Vivo

    Repositioning Market Access: A Function Fit For Purpose In A New Era Of Costly Cures

    By William Looney 15 May 2018

    On October 5, In Vivo convened a group of top market-access specialists and industry and investment analysts to consider a central strategic challenge facing all innovators in biopharma: how to pay for the next wave of cures. Finding the answer first depends on a rebranding of the function itself – it’s not market access to products; it’s patient access to progress.

    Topic Strategy

  • Datamonitor Healthcare

    Datamonitor Healthcare Podcast 16 February 2018

    By Zachary McLellan 15 May 2018

    Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including a recap of the 2018 BIO CEO conference, Phase IIb results of aramchol in HIV-lipodystrophy NAFLD or NASH patients, and the approval of Ereleada (apalutamide) in non-metastatic castration-resistant prostate cancer.

    Topic Business strategies BioPharmaceutical

  • Datamonitor Healthcare

    HIV Market Growth webinar

    By Michael ​ Haydock 15 May 2018

    Mr. Haydock & Mr. Haas used the exclusive information within Datamonitor Healthcare and Biomedtracker to present a view of the market for HIV drugs. Informa Pharma Intelligence forecasts HIV sales revenues to increase in the US and five major EU markets to a peak of $22.7bn in 2024 before generic erosion triggers a market decline.

  • Datamonitor Healthcare

    Datamonitor Healthcare Podcast 04 April 2018

    By Jack Allen 15 May 2018

    Zach McLellan & Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including analysis on Allogene's announcement that they are in-licensing the TALEN technology from Pfizer to commericalise and develop allogeneic, potentially leading to a strong acceleration of CART therapies.

    Topic Drug development landscape

  • Datamonitor Healthcare

    Podcast - Analyst Opinion on Approval of AndexXa for reversal of Eliquis and Xarelto

    By Zachary McLellan 11 May 2018

    Zach McLellan, Jack Allen, and guest analyst Cameron Findlater discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including the approval of AndexXa for reversal of Eliquis and Xarelto & Eli Lilly's acquisition of ARMO Biosciences.

  • In Vivo

    Pharma Sourcing And Procurement: The New Strategy Of Spend

    11 May 2018

    Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise?In Vivotalks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

    Topic BioPharmaceutical

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: